Your browser doesn't support javascript.
loading
Photobiomodulation for melasma treatment: Integrative review and state of the art.
Galache, Thais Rodrigues; Sena, Michelle Mota; Tassinary, João Alberto Fioravante; Pavani, Christiane.
Afiliação
  • Galache TR; Postgraduate Program in Biophotonics Medicine, Universidade Nove de Julho, UNINOVE, São Paulo, SP, Brazil.
  • Sena MM; Postgraduate Program in Biophotonics Medicine, Universidade Nove de Julho, UNINOVE, São Paulo, SP, Brazil.
  • Tassinary JAF; Centro Universitário Univates - CCBS, Lajeado, RS, Brazil.
  • Pavani C; Postgraduate Program in Biophotonics Medicine, Universidade Nove de Julho, UNINOVE, São Paulo, SP, Brazil.
Photodermatol Photoimmunol Photomed ; 40(1): e12935, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38018017
ABSTRACT

PURPOSE:

Photobiomodulation therapy (PBM) is a versatile technique for treating skin diseases. Melasma, a chronic hyperpigmentation condition, has recently been associated with vascular features and dermal photoaging and poses significant management challenges. We review the recent literature on melasma etiology and the evidence supporting PBM as a therapeutic modality for melasma treatment.

METHODS:

We conducted a comprehensive literature search in three different databases from May to August 2023, focusing on studies published in the past 10 years. The inclusion criteria comprised full-text studies investigating low-power lasers and/or light-emitting diodes (LEDs) in in vitro or in vivo models, as well as clinical trials. We excluded studies discussing alternative melasma therapies or lacking experimental data. We identified additional studies by searching the reference lists of the selected articles.

RESULTS:

We identified nine relevant studies. Clinical studies, in agreement with in vitro experiments and animal models, suggest that PBM effectively reduces melasma-associated hyperpigmentation. Specific wavelengths (red 630 nm; amber 585 and 590 nm; infrared 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 exert modulatory effects on tyrosinase activity, gene expression, and protein synthesis of melanocytic pathway components, and thus significantly reduce the melanin content. Additionally, PBM is effective in improving the dermal structure and reducing erythema and neovascularization, features recently identified as pathological components of melasma.

CONCLUSION:

PBM emerges as a promising, contemporary, and non-invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM shows potential in reducing erythema and vascularization and improving dermal conditions. However, robust and well-designed clinical trials are needed to determine optimal light parameters and to evaluate the effects of PBM on melasma thoroughly.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperpigmentação / Terapia com Luz de Baixa Intensidade / Melanose Tipo de estudo: Systematic_reviews Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperpigmentação / Terapia com Luz de Baixa Intensidade / Melanose Tipo de estudo: Systematic_reviews Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article